Results 231 to 240 of about 2,034,935 (392)

Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study

open access: yesBritish Journal of Haematology, EarlyView.
In a population‐based cohort of 149 chronic myelomonocytic leukaemia (CMML) patients, multihit TET2 mutation was associated with older age, lower LDH and less leucocytosis. We found no association with autoimmune disease or thrombosis. Patients with multihit TET2 mutation had a significantly longer overall survival than the patients without or with one
Matilda Kjellander Kynning   +14 more
wiley   +1 more source

Zonulin levels in children with chronic immune thrombocytopenia. [PDF]

open access: yesMedicine (Baltimore)
Karadoğan M   +4 more
europepmc   +1 more source

COVID-19 vaccination and immune thrombocytopenia

open access: yesNature Network Boston, 2021
Allyson M. Pishko, J. Bussel, D. Cines
semanticscholar   +1 more source

Opportunities for improving platelet transfusion practice: A large retrospective audit across 22 hospitals

open access: yesBritish Journal of Haematology, EarlyView.
Summary Despite evidence‐based guidelines to inform platelet transfusion practice, unnecessary platelet transfusion persists. We performed a multicentre retrospective analysis of adults admitted to general medicine, subspecialty medicine and critical care from 1 January 2017 to 30 June 2022.
Sarah Ryan   +14 more
wiley   +1 more source

Immunomodulatory Mechanisms and Therapeutic Potential of Vitamin D in Immune Thrombocytopenia. [PDF]

open access: yesJ Immunol Res
Ma Y   +9 more
europepmc   +1 more source

High pretreatment peripheral blood T‐cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of Haematology

open access: yesBritish Journal of Haematology, EarlyView.
Left panel: Scheme of the XPAG‐immune thrombocytopenia trial. The dexamethasone (DEX) arm consisted of DEX 40 mg/day for days 1–4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag (ETB) + DEX received eltrombopag in combination with a short course of high‐dose DEX beginning on
Paul Schmidt‐Barbo   +24 more
wiley   +1 more source

International consensus report on the investigation and management of primary immune thrombocytopenia.

open access: yesBlood, 2010
D. Provan   +21 more
semanticscholar   +1 more source

IgG lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance [PDF]

open access: yes, 1995
Bronsther, S   +10 more
core  

Home - About - Disclaimer - Privacy